PDCD1 and non-small cell lung carcinoma: The majority of NSCLC cases involving tumors that lack targetable driver mutations, immunotherapy using specific antibodies against programmed cell death protein 1 (PD-1) and its ligand (PD-L1) has been shown to be highly effective, becoming a key first-line treatment option 5-7.